Thrombospondin-2 and uses thereof
1 Assignment
0 Petitions
Accused Products
Abstract
The invention features a method of treating a disorder characterized by unwanted angiogenesis and/or unwanted cellular proliferation, e.g., unwanted skin or prostate cell proliferation, by increasing a TSP-2 activity. The invention also features methods of identifying compounds which modulate, e.g., inhibit or promote, TSP-2 activity, and methods of evaluating if a subject is at risk for a disorder characterized by unwanted angiogenesis and/or unwanted cellular proliferation. The invention also features fragments and analogs of TSP-2 which can by used to treat such disorders.
-
Citations
80 Claims
-
1-55. -55. (canceled)
-
56. A method of treating a subject having an angiogenesis-dependent tumor, the method comprising:
-
identifying a subject having an angiogenesis-dependent tumor; and
administering to the subject a polypeptide comprising a fragment of SEQ ID NO;
2 (TSP-2) or a sequence at least 95% identical to SEQ ID NO;
2, wherein the fragment is capable of inhibiting endothelial cell migration, and comprises at least 10 amino acids of SEQ ID NO;
2 or the sequence at least 95% identical to SEQ ID NO;
2. - View Dependent Claims (57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)
-
-
74. A method of treating an angiogenesis-dependent tumor, the method comprising administering to the subject a fragment of TSP-2 comprising the sequence of SEQ ID NO:
- 10 (WSPWAEW).
-
75. A method of treating a subject having an angiogenesis-dependent tumor, the method comprising:
-
identifying a subject having an angiogenesis-dependent tumor; and
administering to the subject a cell genetically engineered to express TSP-2 (SEQ ID NO;
2) or a fragment thereof, capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 amino acids of TSP-2. - View Dependent Claims (76, 77, 78, 79, 80)
-
Specification